NEW YORK (TheStreet) -- BioDelivery Sciences (BDSI) surged Monday to a 52-week high of $14.38 after the company announced in conjunction with Endo that their experimental painkiller BEMA buprenorphine was effective in a second late-stage trial.
The trial tested the drug against a placebo in 511 patients on regular opioid therapy. Data from the first late-stage trial in January revealed the drug significantly reduced chronic pain in patients who do not regularly take opioids.
BioDelivery and Endo signed an agreement in Jan. 2012 to develop the drug for chronic pain treatment. Endo will make a milestone payment of $10 million to BioDelivery as part of the deal.
Must Read: Warren Buffett's 25 Favorite StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. BioDelivery was up 10.4% to $13.24 at 12:14 p.m. More than 5.2 million shares had changed hands, compared to the average volume of 761,227. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts